Vincristine加上Irinotecan能延長頑固依汶氏肉瘤年輕成人之末期生命

A combined regimen of vincristine plus irinotecan (i.e., VI regimen) was chosen during the search for an effective and affordable treatment for terminal Ewing sarcoma. We report our experience of prescribing four courses of VI for a 21-year-old man diagnosed with refractory Ewing sarcoma of the righ...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	童綜合醫學雜誌 2020-12, Vol.14 (2), p.093-097
Hauptverfasser:	謝雯伶(Wen-Ling Hsieh), 顏秀如(Hsiu-Ju Yen), 洪君儀(Giun-Yi Hung)
Format:	Artikel
Sprache:	chi
Schlagworte:	chemotherapy Ewing sarcoma irinotecan relapsed vincristine 依汶氏肉瘤化學治療復發
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

container_end_page	097
container_issue	2
container_start_page	093
container_title	童綜合醫學雜誌
container_volume	14
creator	謝雯伶(Wen-Ling Hsieh) 顏秀如(Hsiu-Ju Yen) 洪君儀(Giun-Yi Hung)
description	A combined regimen of vincristine plus irinotecan (i.e., VI regimen) was chosen during the search for an effective and affordable treatment for terminal Ewing sarcoma. We report our experience of prescribing four courses of VI for a 21-year-old man diagnosed with refractory Ewing sarcoma of the right sacrum with multiple metastases. In addition to dramatically reducing his tumor fever and systemic inflammation, his life was extended for five months longer than expected. Based on this case, we suggest considering using VI regimens in Ewing sarcoma not only for life-extending purposes but also as a first-line therapy for newly diagnosed high-risk patients.
format	Article
fullrecord	<record><control><sourceid>hyweb</sourceid><recordid>TN_cdi_hyweb_hyread_00574777</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>00574777</sourcerecordid><originalsourceid>FETCH-hyweb_hyread_005747773</originalsourceid><addsrcrecordid>eNpjYeA0MjA31DU2tTTiYOAtLs5MMjAyMDaytDQz5mQICcvMSy7KLC7JzEt92rXgyY4uz6LMvPyS1OTEvBfNe5_u3vZy6vaXCyY-nb3ryb65zzZue7ah_0VT5_MZS57u3PJiz9RnHROe7Nr1ZGf3szmrn82Z_3zK_KcT9_IwsKYl5hSn8kJpbgYZN9cQZw_djMry1KT4jMqi1MSUeAMDU3MTc3NzYwLSACbKUic</addsrcrecordid><sourcetype>Publisher</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Vincristine加上Irinotecan能延長頑固依汶氏肉瘤年輕成人之末期生命</title><source>DOAJ Directory of Open Access Journals</source><creator>謝雯伶(Wen-Ling Hsieh) ; 顏秀如(Hsiu-Ju Yen) ; 洪君儀(Giun-Yi Hung)</creator><creatorcontrib>謝雯伶(Wen-Ling Hsieh) ; 顏秀如(Hsiu-Ju Yen) ; 洪君儀(Giun-Yi Hung)</creatorcontrib><description>A combined regimen of vincristine plus irinotecan (i.e., VI regimen) was chosen during the search for an effective and affordable treatment for terminal Ewing sarcoma. We report our experience of prescribing four courses of VI for a 21-year-old man diagnosed with refractory Ewing sarcoma of the right sacrum with multiple metastases. In addition to dramatically reducing his tumor fever and systemic inflammation, his life was extended for five months longer than expected. Based on this case, we suggest considering using VI regimens in Ewing sarcoma not only for life-extending purposes but also as a first-line therapy for newly diagnosed high-risk patients.</description><description>在兼顧治療效益與經濟成本的考量之下，我們選擇vincristine加上irinotecan的組合方案（VI組合）治療一位依汶氏肉瘤的末期病人。一名21歲男性罹患右薦椎的頑固型依汶氏肉瘤，合併多重轉移，我們處方了四次VI組合的療程，除了戲劇化的成功緩解腫瘤熱和系統性發炎外，他的壽命更比預期延長了五個月。基於在這個案例的發現，我們認為在新診斷的高風險依汶氏肉瘤病人身上，VI組合可以被考慮使用於一線治療，而非只是擔任延長生命的角色</description><identifier>ISSN: 2071-3592</identifier><language>chi</language><publisher>台灣: 童綜合醫學雜誌社</publisher><subject>chemotherapy ; Ewing sarcoma ; irinotecan ; relapsed ; vincristine ; 依汶氏肉瘤 ; 化學治療 ; 復發</subject><ispartof>童綜合醫學雜誌, 2020-12, Vol.14 (2), p.093-097</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784</link.rule.ids></links><search><creatorcontrib>謝雯伶(Wen-Ling Hsieh)</creatorcontrib><creatorcontrib>顏秀如(Hsiu-Ju Yen)</creatorcontrib><creatorcontrib>洪君儀(Giun-Yi Hung)</creatorcontrib><title>Vincristine加上Irinotecan能延長頑固依汶氏肉瘤年輕成人之末期生命</title><title>童綜合醫學雜誌</title><description>A combined regimen of vincristine plus irinotecan (i.e., VI regimen) was chosen during the search for an effective and affordable treatment for terminal Ewing sarcoma. We report our experience of prescribing four courses of VI for a 21-year-old man diagnosed with refractory Ewing sarcoma of the right sacrum with multiple metastases. In addition to dramatically reducing his tumor fever and systemic inflammation, his life was extended for five months longer than expected. Based on this case, we suggest considering using VI regimens in Ewing sarcoma not only for life-extending purposes but also as a first-line therapy for newly diagnosed high-risk patients.</description><description>在兼顧治療效益與經濟成本的考量之下，我們選擇vincristine加上irinotecan的組合方案（VI組合）治療一位依汶氏肉瘤的末期病人。一名21歲男性罹患右薦椎的頑固型依汶氏肉瘤，合併多重轉移，我們處方了四次VI組合的療程，除了戲劇化的成功緩解腫瘤熱和系統性發炎外，他的壽命更比預期延長了五個月。基於在這個案例的發現，我們認為在新診斷的高風險依汶氏肉瘤病人身上，VI組合可以被考慮使用於一線治療，而非只是擔任延長生命的角色</description><subject>chemotherapy</subject><subject>Ewing sarcoma</subject><subject>irinotecan</subject><subject>relapsed</subject><subject>vincristine</subject><subject>依汶氏肉瘤</subject><subject>化學治療</subject><subject>復發</subject><issn>2071-3592</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><recordid>eNpjYeA0MjA31DU2tTTiYOAtLs5MMjAyMDaytDQz5mQICcvMSy7KLC7JzEt92rXgyY4uz6LMvPyS1OTEvBfNe5_u3vZy6vaXCyY-nb3ryb65zzZue7ah_0VT5_MZS57u3PJiz9RnHROe7Nr1ZGf3szmrn82Z_3zK_KcT9_IwsKYl5hSn8kJpbgYZN9cQZw_djMry1KT4jMqi1MSUeAMDU3MTc3NzYwLSACbKUic</recordid><startdate>202012</startdate><enddate>202012</enddate><creator>謝雯伶(Wen-Ling Hsieh)</creator><creator>顏秀如(Hsiu-Ju Yen)</creator><creator>洪君儀(Giun-Yi Hung)</creator><general>童綜合醫學雜誌社</general><scope>9RA</scope></search><sort><creationdate>202012</creationdate><title>Vincristine加上Irinotecan能延長頑固依汶氏肉瘤年輕成人之末期生命</title><author>謝雯伶(Wen-Ling Hsieh) ; 顏秀如(Hsiu-Ju Yen) ; 洪君儀(Giun-Yi Hung)</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-hyweb_hyread_005747773</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>chi</language><creationdate>2020</creationdate><topic>chemotherapy</topic><topic>Ewing sarcoma</topic><topic>irinotecan</topic><topic>relapsed</topic><topic>vincristine</topic><topic>依汶氏肉瘤</topic><topic>化學治療</topic><topic>復發</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>謝雯伶(Wen-Ling Hsieh)</creatorcontrib><creatorcontrib>顏秀如(Hsiu-Ju Yen)</creatorcontrib><creatorcontrib>洪君儀(Giun-Yi Hung)</creatorcontrib><collection>HyRead台灣全文資料庫</collection><jtitle>童綜合醫學雜誌</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>謝雯伶(Wen-Ling Hsieh)</au><au>顏秀如(Hsiu-Ju Yen)</au><au>洪君儀(Giun-Yi Hung)</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Vincristine加上Irinotecan能延長頑固依汶氏肉瘤年輕成人之末期生命</atitle><jtitle>童綜合醫學雜誌</jtitle><date>2020-12</date><risdate>2020</risdate><volume>14</volume><issue>2</issue><spage>093</spage><epage>097</epage><pages>093-097</pages><issn>2071-3592</issn><abstract>A combined regimen of vincristine plus irinotecan (i.e., VI regimen) was chosen during the search for an effective and affordable treatment for terminal Ewing sarcoma. We report our experience of prescribing four courses of VI for a 21-year-old man diagnosed with refractory Ewing sarcoma of the right sacrum with multiple metastases. In addition to dramatically reducing his tumor fever and systemic inflammation, his life was extended for five months longer than expected. Based on this case, we suggest considering using VI regimens in Ewing sarcoma not only for life-extending purposes but also as a first-line therapy for newly diagnosed high-risk patients.</abstract><abstract>在兼顧治療效益與經濟成本的考量之下，我們選擇vincristine加上irinotecan的組合方案（VI組合）治療一位依汶氏肉瘤的末期病人。一名21歲男性罹患右薦椎的頑固型依汶氏肉瘤，合併多重轉移，我們處方了四次VI組合的療程，除了戲劇化的成功緩解腫瘤熱和系統性發炎外，他的壽命更比預期延長了五個月。基於在這個案例的發現，我們認為在新診斷的高風險依汶氏肉瘤病人身上，VI組合可以被考慮使用於一線治療，而非只是擔任延長生命的角色</abstract><cop>台灣</cop><pub>童綜合醫學雜誌社</pub></addata></record>
fulltext	fulltext
identifier	ISSN: 2071-3592
ispartof	童綜合醫學雜誌, 2020-12, Vol.14 (2), p.093-097
issn	2071-3592
language	chi
recordid	cdi_hyweb_hyread_00574777
source	DOAJ Directory of Open Access Journals
subjects	chemotherapy Ewing sarcoma irinotecan relapsed vincristine 依汶氏肉瘤化學治療復發
title	Vincristine加上Irinotecan能延長頑固依汶氏肉瘤年輕成人之末期生命
url	https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-22T22%3A12%3A29IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-hyweb&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Vincristine%E5%8A%A0%E4%B8%8AIrinotecan%E8%83%BD%E5%BB%B6%E9%95%B7%E9%A0%91%E5%9B%BA%E4%BE%9D%E6%B1%B6%E6%B0%8F%E8%82%89%E7%98%A4%E5%B9%B4%E8%BC%95%E6%88%90%E4%BA%BA%E4%B9%8B%E6%9C%AB%E6%9C%9F%E7%94%9F%E5%91%BD&rft.jtitle=%E7%AB%A5%E7%B6%9C%E5%90%88%E9%86%AB%E5%AD%B8%E9%9B%9C%E8%AA%8C&rft.au=%E8%AC%9D%E9%9B%AF%E4%BC%B6(Wen-Ling%20Hsieh)&rft.date=2020-12&rft.volume=14&rft.issue=2&rft.spage=093&rft.epage=097&rft.pages=093-097&rft.issn=2071-3592&rft_id=info:doi/&rft_dat=%3Chyweb%3E00574777%3C/hyweb%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true